Report Predicts Global Psychedelic Drugs Market Will Reach $22.6B by 2033 – Ganjapreneur | How to buy Skittles Moonrock online

The international psychedelic drugs market, estimated at $7.4 billion globally in 2025, is expected to grow to $22.6 billion by 2033, according to a report published in Research and Markets.

The report covered both synthetic and natural psychedelics that are under investigation for mental health therapy, including psilocybin, LSD, MDMA, ketamine, and DMT. Recent research has found that certain psychedelic substances show promise in treating mental health conditions like post-traumatic stress syndrome (PTSD and treatment-resistant depression.

Researchers calculated the market for products manufactured for medicinal and research purposes and recreational purposes, focusing on online retailers, pharmacies, and specialty stores or dispensaries as the industry’s distribution channels.

With an annual growth rate (CAGR) of 15%, the report authors said the rapid expansion is thanks to a growing research base and a significant shift in public opinion regarding the potential benefits of psychedelics. Additionally, the authors predicted that innovations in delivery formats and digital health platforms would drive additional growth, highlighting Europe and Latin America “as key growth regions with performing policy reforms and enhanced clinical infrastructure.”

The report considered the psychedelic markets in specific countries, including the United States, Canada, Mexico, Germany, the United Kingdom, France, Spain, Italy, China, India, Japan, Australia, Brazil, and Argentina, with wider attention to the Middle East, Africa, and South and Central America.

In the U.S., the therapeutic use of psilocybin — the naturally occurring chemical in psychedelic mushrooms — is legal in Oregon and Colorado.

Based in Portland, Oregon, Graham is Ganjapreneur’s Chief Editor. He has been writing about the legalization landscape since 2012 and has been contributing to Ganjapreneur since our official launch in… More by Graham Abbott